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Abstract
Bone density is controlled by interactions between osteoclasts, which resorb bone, and
osteoblasts, which deposit it. The semaphorins and their receptors, the plexins, originally
shown to function in the immune system and to provide chemotactic cues for axon guid-
ance, are now known to play a role in this process as well. Emerging data have identified
Semaphorin 4D (Sema4D) as a product of osteoclasts acting through its receptor Plexin-B1
on osteoblasts to inhibit their function, tipping the balance of bone homeostasis in favor of
resorption. Breast cancers and other epithelial malignancies overexpress Sema4D, so we
theorized that tumor cells could be exploiting this pathway to establish lytic skeletal metasta-
ses. Here, we use measurements of osteoblast and osteoclast differentiation and function
in vitro and a mouse model of skeletal metastasis to demonstrate that both soluble Sema4D
and protein produced by the breast cancer cell line MDA-MB-231 inhibits differentiation of
MC3T3 cells, an osteoblast cell line, and their ability to form mineralized tissues, while
Sema4D-mediated induction of IL-8 and LIX/CXCL5, the murine homologue of IL-8,
increases osteoclast numbers and activity. We also observe a decrease in the number of
bone metastases in mice injected with MDA-MB-231 cells when Sema4D is silenced by
RNA interference. These results are significant because treatments directed at suppression
of skeletal metastases in bone-homing malignancies usually work by arresting bone remod-
eling, potentially leading to skeletal fragility, a significant problem in patient management.
Targeting Sema4D in these cancers would not affect bone remodeling and therefore could
elicit an improved therapeutic result without the debilitating side effects.
Introduction
The semaphorins and their receptors, the plexins, represent a large family of phylogenetically
conserved molecules, both secreted and membrane bound, containing a large, cysteine-rich
sema domain that were originally identified based on their ability to provide both attractive
and repulsive axon guidance cues during neural development. Plexin-semaphorin interactions
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now have been implicated in a host of responses, including loss of cell-cell contact and branch-
ing morphogenesis in epithelium, alterations in cell adhesion, regulation of lymphocyte activa-
tion, and development of the heart and vasculature [1]. There are more than 30 semaphorins
identified to date classified into 8 subgroups based on their species of origin and sequence simi-
larity, and nine known plexins, Plexin-A1 to -A4, -B1 to -B3, -C1, and -D1, grouped according
to domain structure, that exhibit promiscuity in binding and generate varying effects depend-
ing on availability and tissue and cell type. Semaphorin 4D (Sema4D) is an immune sema-
phorin expressed by T-lymphocytes and eosinophils and to a lesser extent by dendritic cells
and B-lymphocytes but is also found in nerve tissues, the gonads, kidney, heart, lung and else-
where, though it has not been found in normal breast epithelium or breast stroma [2]. Our lab
and others have shown that it is pro-angiogenic when acting through its receptor, Plexin-B1 on
endothelial cells [3,4], and may be produced by malignancies in hypoxia or through aberrant
expression of hypoxia inducible factor-1 for the purposes of promoting blood vessel growth
into a tumor in a manner analogous to vascular endothelial growth factor [5].
Remodeling of the adult skeleton is controlled by osteoclasts, which resorb bone, and osteo-
blasts, which deposit bone matrix, and the factors they produce and that are released by the
extracellular matrix that mediate this process. Recent studies have identified Sema4D in the
bone microenvironment and demonstrate that it is a product of osteoclasts that acts through
Plexin-B1 on osteoblasts to inhibit their differentiation and motility [6]. Indeed, Sema4D
knockout mice exhibit an osteosclerotic phenotype [6], so this signaling pathway may represent
a potential target in the treatment of osteoporosis. However, because excess Sema4D could tip
the balance of bone homeostasis in favor of resorption, and we have observed that many carci-
nomas overexpress Sema4D [7], we wanted to examine if tumor cells could be using this path-
way to establish lytic metastatic lesions in the skeleton. It is known that in bone loss associated
with neoplasia, a decrease in bone formation is observed in addition to enhanced tumor and
osteoclastic resorption [8]. For example, breast cancer cells secrete factors that inhibit osteo-
blast differentiation and activity [9], influencing their ability to establish lytic skeletal metasta-
ses and resulting in pathologic fractures, hypercalcemia and other skeletal related events, a
known complication of this disease and other bone-homing malignancies.
Here we show that breast cancer cell lines express high levels of Sema4D relative to their
ability to spread to bone and that both soluble (s)Sema4D and Sema4D derived from
MDA-MB-231 cells inhibits differentiation and ability to form mineralized matrix by MC3T3
cells, an osteoblast pre-cursor cell line. Our group has shown previously that Sema4D induces
production of IL-8 in treated cells [10]. We demonstrate that human and mouse osteoblasts
produce IL-8 and lipopolysaccharide-induced CXC (LIX)/CXCL5, the murine homologue of
IL-8, respectively, in response to Sema4D, which alone or in combination with RANK-L acti-
vates osteoclasts [11], further stimulating bone resorption. Finally, we observed suppression of
skeletal spread in a mouse model of metastasis, and increased osteoblasts and decreased num-
bers of osteoclasts in lesional tissues comprised of MDA-MB-231 cells with silenced Sema4D
compared to controls.
Mortality due to cancer is usually related to distant metastasis, so many therapies are
directed against this aspect of tumor spread. In bone-homing malignancies, bisphosphonates
are used to suppress skeletal metastases, but this form of treatment inhibits osteoclasts and
arrests bone remodeling, leading to skeletal fragility and osteonecrosis of the jaw. The results
presented here suggest that targeting Sema4D for inhibition could be a viable alternative, since
it would not greatly affect skeletal remodeling and therefore could elicit an improved therapeu-
tic result without the debilitating side effects.
Sema4D and Breast Cancer Metastasis
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Materials and Methods
Cell culture
MC3T3-E1 cells (ATCC, Manassas, VA) were maintained in Alpha Minimum Essential
Medium (Gibco); 293T (ATCC) and breast cancer cell lines (ATCC) were cultured in DMEM
(Sigma, St. Louis, MO); Murine macrophage cell line Raw 264.7 were cultured in RPMI 1640
(Sigma). All media were supplemented with 10% fetal bovine serum (unless otherwise noted)
and 100 units/ml penicillin/streptomycin (Sigma) and treated as indicated. Human Osteoblasts
(HOB) and osteoblast growth medium were obtained from PromoCell (Heidelberg, Germany).
Purification of soluble Sema4D
Soluble Sema4D (sSema4D) was produced and purified as described previously [3]. Briefly, the
extracellular portion of Sema4D was subjected to PCR and the resulting product cloned into
the plasmid pSecTag2B (Invitrogen, Carlsbad, CA). This construct was transfected into 293T
cells growing in serum free media. Media containing sSema4D was collected 65 h post-trans-
fection and purified with TALONmetal affinity resin (Clontech Laboratories, Palo Alto, CA)
according to manufacturer’s instructions. Concentration and purity of the TALON eluates was
determined by SDS PAGE analysis followed by silver staining (Amersham Life Science, Piscat-
away, NJ), comparing band intensity against a BSA standard curve on the same gel, and the
Bio-Rad protein assay (Bio-Rad, Hercules, CA). In all cases, media collected from cells trans-
fected with the empty pSecTag2B vector were used as control.
Alkaline phosphatase assay
Differentiation of MC3T3-E1 cells growing in increasing concentrations of sSema4D was
determined by alkaline phosphatase (AP) activity as previously described [12]. Results are
expressed as the average and standard deviation for three independent experiments.
Mineralization assay
Mineralization of MC3T3-E1 cells was determined by Alizarin red (Sigma) in 6-well plate as
previously described [13,14]. Briefly, cells were grown to confluency in α-MEM containing
10% fetal bovine serum and 100 units/ml penicillin/streptomycin with osteogenic supplements
(50 μM ascorbic acid, 10 nM dexamethasone and 10 mM β-Glycerophosphate) with or without
sSema4D or media conditioned by the breast cancer cell lines MDA-MB-231 and MCF-12A
and 5 μg/ ml anti-Sema4D antibody (Vaccinex), where indicated. Cultures were incubated at
37°C with 5% CO2 with changes of medium every 3 days for 3 weeks. Then, the monolayers
were washed with PBS and fixed in 4% paraformaldehyde at room temperature for 15 min. and
stained with Alizarin red. For quantitation, photos were taken and stained monolayers were
detached from the plate using acetic acid and then transferred to a 1.5 ml Eppendorf tube. The
slurry was heated to 85°C for 10 min., and put on ice for 5 min. The supernatant was trans-
ferred to a 95-well plate and read in triplicate at 405 nm in a microplate reader.
Immunoblots and detection of shed Sema4D
The indicated cell lines were grown in serum free media, lysed in buffer (50 mM Tris-HCl, 150
mMNaCl, 1% NP 40 supplemented with protease inhibitors (0.5 mM phenylmethylsulfonyl
fluoride, 1 μl/ml aprotinin and leupeptin, Sigma) and phosphatase inhibitors (2 mM NaF and
0.5 mM sodium orthovanadate, Sigma)) for 15 min. at 4°C. After centrifugation, protein con-
centrations were measured using the Bio-Rad protein assay (Bio-Rad). 100 μg of protein from
each sample was subjected to SDS-polyacrylamide gel electrophoresis and transferred onto a
Sema4D and Breast Cancer Metastasis
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PVDF membrane (Immobilon P, Millipore Corp., Billerica, MA). The membranes were then
incubated with anti-Sema4D antibody (BD Transduction Labs, BD Biosciences, Palo Alto,
CA), anti-Plexin-B1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or GAPDH
(Sigma). Proteins were detected using the ECL chemiluminescence system (Pierce, Rockford,
IL). For detection of shed Sema4D, 4.5 ml of serum free media was placed on MDA-MB-231 or
MCF-12A cells, controls or with silenced or overexpressed Sema4D, respectively, growing in
10 cm dishes and left overnight to concentrate protein released into the media. Sample buffer
was added directly to the media collected the following day and 50 μl loaded for gel electropho-
resis, with protein detected by silver stain (Amersham), as previously described [15].
IL-8 and LIX/CXCL5 ELISA
ELISA was performed on HOB and MC3T3 cells as previously described [10]. Briefly, conflu-
ent HOB and MC3T3 were serum starved for 4 h, then cultured in serum free medium with
increasing concentrations of sSema4D. Conditioned media were collected at the indicated time
points and used to analyze IL-8 and LIX/CXCL5 production by ELISA by the Cytokine Core
Facility, University of Maryland School of Medicine. Where indicated, the assay was performed
in the presence of media conditioned by serum starved MDA-MB-231 cells with or without
6 μg/ml C3 toxin (List Biological Laboratories, Campbell, CA). Results are expressed as the
average and standard deviation for three independent experiments.
Osteoclastogenesis assay
2x105 pre-osteoblast RAW 264.7 cells were cultured in each well of a 12-well plate along with
RANKL, IL-8, or medium conditioned by HOB treated with 400 ng/ml sSema4D or empty vec-
tor transfected controls and 10 μg/ml anti-IL-8 antibody (Lifespan Biosciences), where indi-
cated, for 6 days with media changed every other day. The cells were fixed and tartrate-
resistant acid phosphatase (TRAP) staining was conducted using an acid phosphatase, leuko-
cyte (TRAP) kit (Sigma) as previously described [16]. Multinucleated TRAP positive cells were
counted as mature osteoclasts in microscopic high power fields. Results are expressed as the
average and standard deviation for three independent experiments.
Short hairpin (sh) RNA, overexpression, and lentivirus infections
The shRNA sequences for human Sema4D and murine Plexin-B1 were obtained from Cold
Spring Harbor Laboratory's RNAi library (RNAi Central, http://cancan.cshl.edu/RNAi_
central/RNAi.cgi?type=shRNA) [17,18]. Four sequences were used as PCR templates, with the
one best silencing the gene of interest chosen for the experiments, as previously reported [7].
Oligos were synthesized (Invitrogen) and cloned into pWPI GW, a Gateway compatible CSCG
based lentiviral destination vector as previously described [7,19,20]. Viruses coding for scram-
bled sequences were used as controls for all lentivirus infections. Viral stocks were prepared
and infections performed as previously reported [7]. Cells were checked for viability following
lentiviral infections and knockdown was confirmed by immunoblot. For Sema4D overexpres-
sion, the extracellular portion of Sema4D was cloned into pSHAGMAGIC2, an entry vector
for the Gateway cloning system, and then an LR reaction performed to transfer the inserts into
pWPI GW (Invitrogen), as previously described [15].
Tumor xenografts and bioluminescence imaging
To minimize animal suffering and distress during the grafting procedure, mice were anesthe-
tized with i.p. administration of Avertin anesthesia. An injection site was prepared with an
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antiseptic povidone iodine scrub and alcohol rinse and 1 x 105 MDA-MB-231 cells, infected ex
vivo with control virus or lentivirus coding for Sema4D shRNA, were injected into the left car-
diac ventricle with a sterile tuberculin syringe with a 25 gauge needle (5/8”) as previously
reported [21]. A power analysis based upon published results indicated that 10 mice were
required per experimental condition but 11 were used because of an approximately 10% mor-
tality rate for intracardiac injections. However, no adverse effects or animal deaths occurred
during grafting. For bioluminescence imaging (BLI), mice were temporarily anesthetized using
2.0–2.5% veterinarian grade isoflurane administered in a dedicated XGI-8 gas inhalation anes-
thesia apparatus. Once sedated, ocular protectant was applied every 30 minutes, with depth of
anesthesia determined by monitoring respiration rate and responsiveness to toe pinch stimuli.
Intraperitoneal injections of 100 mg/ml D-luciferin (Xenogen) in PBS were administered to
track development of bone metastasis. Images were acquired with a Xenogen IVIS 200 imaging
system. For analysis, total photon flux (photons per second) was measured from tumor areas
located in the hind limb joints [22,23]. Metastatic lesions formed in control populations 2 to 3
weeks after introduction of tumor cells and were allowed to grow to a measureable size amena-
ble for histopathological analysis (approximately 5 weeks). Mice were monitored every three
days as well as on days of bioluminescence (which occurred once a week) for body weight,
activity level, ambulation, posture and general overall appearance. The endpoint criteria for
euthanizing mice were as follows: any tumor growth that interfered with normal ambulation or
sleeping; the inability to drink or eat food; a loss of 20% or more of body weight; tumors caus-
ing a mouse to exhibit hydrothorax or hydro-abdomen development to the point of respiratory
compromise; a moribund state as indicated by lack of movement to light tapping; mice show-
ing saturating luminescence signals greater than 109 photons/sec/cm2 for tumor deposits.
Euthanasia was carried out using CO2 inhalation followed by cervical dislocation, after which
tumors were removed for further sectioning and processing (see below). All animal studies
were approved by the University of Maryland Office of Animal Welfare, Institutional Animal
Care and Use Committee, in accordance with the NIH Guide for the Care and Use of Labora-
tory Animals.
Radiographs
Osteolysis was assessed by X-ray analysis. High resolution digital radiographs (30 kV, 10 s) of
hind limbs were performed on anesthetized mice with a Faxitron Digital X-ray system (Faxi-
tron X-Ray, Lincolnshire, IL) as previously described [24], with osteolytic lesions expressed as
a percentage of the total tissue area measured using NIH Image J software.
Serum and supernatant biochemistry
The levels of RANKL, OPG, LIX/CXCL5, IL-8 and osteocalcin (OCN) in the serum and condi-
tioned medium of cultured MC3T3 and HOB cells were determined by ELISA (R&D Systems,
Minneapolis, MN, and Immutopic International, San Clemente, CA) as previously described
[10]. AP activity was assayed using the SensoLyte pNPP alkaline phosphatase assay kit (Ana-
Spec, Fremont, CA). Results are expressed as the average and standard deviation for three inde-
pendent experiments.
Immunohistochemistry and bone histomorphometric analysis
Hind limb bones were harvested from mice and fixed in 4% paraformaldehyde, decalcified in
0.5M EDTA for 2 weeks, and embedded in paraffin. H&E and TRAP stain (with counterstain)
was used for identification of osteoclasts and osteoblasts, and an estimate of the number of
osteoblasts per trabecular and cortical area (number/mm2) was performed based upon
Sema4D and Breast Cancer Metastasis
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methods previously described [25]. Bone histomorphometry was performed on tumor-bearing
hind limb sections using the Osteomeasure bone histomorphometry system (Osteometrix,
Atlanta, GA) [22,26]. Analysis of bone volume versus total tissue volume, the number of osteo-
clasts per bone surface, and the number of osteoblasts per bone surface was assessed according
to the recommended nomenclature of the American Society for Bone and Mineral Research
[27]. Immunochemical analysis for Sema4D was performed as previously reported [7]. Image
acquisition was performed on a Nikon Eclipse E800 Microscope (Nikon, Melville, NY) using
10x and 40x objective lenses.
Statistical Analysis
Student’s paired t tests were performed on means, and p values calculated: , p 0.05; , p 0.01.
Results
Sema4D inhibits osteoblasts in a Plexin-B1-dependent manner
It has been previously shown that Sema4D, originally identified as an immunomodulator and an
axon guidance molecule, is produced by osteoclasts and can bind to its receptor Plexin-B1 on oste-
oblasts to inhibit their motility and ability to produce osteoid and, subsequently, new bone [6]. To
confirm these findings, we examinedMC3T3 osteoblast precursor cells incubated in sSema4D for
prevention of differentiation by an alkaline phosphatase (AP) assay and loss of ability to produce
matrix in a mineralization assay.We observed a decrease in AP activity (Fig 1A) and deposition of
mineralized matrix (Fig 1B, Alizarin Red stain, inset) in MC3T3 growing under conditions favor-
ing differentiation and mineralization when incubated with sSema4D, in a dose-dependent man-
ner. Inhibition was dependent upon Sema4D binding to Plexin-B1 since this effect was lost in
MC3T3 cells where Plexin-B1 was silenced with short hairpin (sh)RNA (Fig 1C, Plexin-B1
shRNA, lower panel, second row; knockdown confirmed by immunoblot, top panel), or where cells
were incubated with an anti-Sema4D blocking antibody (Fig 1C, lower panel, last row), an anti-
body that our group and others have shown to block interaction with Plexin-B1 and inhibit
Sema4D functioning in angiogenesis, tumor growth, and immunomodulation [28–30]. The results
of the mineralization assay are quantified in the bar graph in Fig 1D. Taken together, these results
confirm that Sema4D, acting through Plexin-B1, inhibits the ability of osteoblasts to form bone.
Sema4D-mediated production of IL-8 by osteoblasts stimulates
osteoclastogenesis
Many factors mediate communication between osteoclasts and osteoblasts to balance bone
resorption and formation. We further examined the effects of Sema4D on osteoblast-osteoclast
communication by looking for changes in levels of well-known mediators of bone homeostasis
by ELISA. The human osteoblast cell line HOB failed to show any changes in RANK-L or OPG
when treated with sSema4D (data not shown) but we did note a robust increase in IL-8 produc-
tion occurring in a dose-dependent manner (Fig 2A). These results were confirmed over a time
course in an IL-8 ELISA (Fig 2B). We have previously linked Sema4D/ Plexin-B1 signaling to
generation of IL-8 (in endothelial cells) [10] and IL-8 is believed to stimulate osteoclast activity
[11]. Indeed, Sema4D has been linked with the promotion of osteoclastogenesis and pathologi-
cal bone resorption [31]. To determine if IL-8 could drive differentiation of the monocyte cell
line RAW 264.7 towards osteoclasts, we looked for tartrate-resistant acid phosphatase (TRAP)
positivity, an indicator of osteoclast differentiation, in cells grown with IL-8, and determined
their ability to fuse into large multinucleated mature osteoclasts in vitro. Results indicate that
IL-8 does, in fact, promote RAW 264.7 differentiation (Fig 2C) and fusion into mature, multi-
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nucleated cells (Fig 2D), an effect independent of, but augmented by the addition of RANK-L.
This could be prevented by co-incubation with anti-IL-8 antibody (Fig 2E, TRAP quantifica-
tion shown in the bar graph, right panel). These results show that in addition to inhibiting oste-
oblasts, Sema4D can also simultaneously stimulate osteoclasts through IL-8, conditions
strongly favoring bone resorption.
Sema4D induces production of LIX/CXCL5 by osteoblasts, which
stimulates osteoclastogenesis
LIX/CXCL5 is the murine homologue of human IL-8 [32]. To determine if Sema4D could
induce production of this factor from murine osteoblasts, and to measure the effects on osteo-
clasts, we grew MC3T3 cells in increasing concentrations of sSema4D. An ELISA for LIX/
Fig 1. Sema4D inhibits osteoblast differentiation and function in a Plexin-B1-dependent manner. A. Alkaline phosphatase activity (Y-axis), a marker of
osteoblastic differentiation, decreases in osteoblasts in increasing concentrations of soluble (s)Sema4D. B. Absorbance of Alizarin Red (optical density (OD)
at 405 nm, Y-axis), which stains mineralized substrate (representative photos shown in the inset), decreases in increasing concentrations of sSema4D for
cells growing under differentiating conditions. C.MC3T3-mediated matrix deposition and mineralization is inhibited by sSema4D.When Plexin-B1 is silenced
with short hairpin (sh) RNA (PB1 shRNA, second row, knockdown confirmed by immunoblot, top), or anti-Sema4D blocking antibody is administered (bottom
row), mineralization in the presence of sSema4D is restored. Isotype matched IgG was used as a control (top rows). D.Quantification of results by
absorbance at 405 nm (Y-axis) of the results shown in C. For all bar graphs *, p 0.05; **, p 0.01.
doi:10.1371/journal.pone.0150151.g001
Sema4D and Breast Cancer Metastasis
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Fig 2. Sema4D stimulates production of IL-8 from osteoblasts, which promotes osteoclast differentiation. A. sSema4D treatment of the human
osteoblast line HOB induces production of IL-8 in a dose-dependent manner (IL-8 concentration in ng/ml, Y-axis).B. An IL-8 ELISA performed on media
conditioned by sSema4D treated HOB confirms this increase (Y-axis, arbitrary units (AU)) out to 24 hrs.C. IL-8 promotes osteoclastogenesis of RAW264.7
cells, particularly in the presence of RANK-L. TRAP assay is shown on top (inset) with the results quantified in the bar graph (average number of TRAP
Sema4D and Breast Cancer Metastasis
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CXCL5 detected increasing concentrations of this protein in conditioned media (Fig 3A), simi-
lar to the results observed in HOB for IL-8. A TRAP assay using media conditioned by sSe-
ma4D treated cells demonstrated increased positivity compared to controls (Fig 3B) and a
greater number of large, multinucleated osteoclasts in culture (Fig 3C). Taken together, these
results suggest that Sema4D-induced LIX/CXCL5 has osteoclastogenic effects in mice.
Breast cancer cell lines produce Sema4D, which inhibits bone
deposition and promotes RhoA-dependent IL-8 production by
osteoblasts
We have previously shown that breast cancers overexpress Sema4D [7]. These results were also
seen in an immunoblot of a panel of breast cancer lines relative to their ability to spread to
positive osteoclasts/ field, Y-axis).D. RAW264.7 cells are observed to fuse into multinucleated osteoclasts in the presence of IL-8. RANK-L enhances this
response. E.Media conditioned by sSema4D treated osteoblasts induces osteoclastogenesis of RAW264.7 cells, a response lost in the presence of IL-8
blocking antibody, demonstrating the importance of this cytokine in differentiation. C, RAW264.7 treated with media conditioned by control osteoblasts
(vehicle control), first column. Isotype matched IgG, second column. Anti-IL8 antibody, third and fourth columns. TRAP assay, left; Quantification, right
(*, p 0.05; **, p 0.01).
doi:10.1371/journal.pone.0150151.g002
Fig 3. LIX/CXCL5, the murine homologue of IL-8, is produced by MC3T3 in the presence of sSema4D
and promotes osteoclastogenesis. A. An ELISA performed on MC3T3 revealed increasing concentrations
of LIX/CXCL5 (LIX, pg/ml, Y-axis) in increasing concentrations of sSema4D.B.Media conditioned by
sSema4D treated MC3T3 (CM) induces osteoclastogenesis of RAW264.7 cells, compared to controls (C).
TRAP assay, top; Quantification of results, bottom (average number of TRAP positive osteoclasts/ field, Y-
axis; *, p 0.05; **, p 0.01).C. RAW264.7 cells are observed to fuse into multinucleated osteoclasts in the
presence of media conditioned by sSema4D treated MC3T3.
doi:10.1371/journal.pone.0150151.g003
Sema4D and Breast Cancer Metastasis
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bone in experimental models. MDA-MB-231 cells, a human breast cancer cell line that forms
osteolytic bone metastases when inoculated into the arterial circulation of mice [33], expresses
high levels of Sema4D relative to MCF-12A or T47D cells, lines which do not spread to bone
(Fig 4A). To determine if Sema4D from breast cancer cell lines can affect osteoblast-mediated
mineralization, we needed to alter production of this protein. MDA-MB-231 cells infected with
lentivirus coding for a scrambled shRNA construct produce high levels of endogenous Sema4D
in whole cell lysates (Fig 4B, top left panel, first lane, C), which we could silence in cells infected
with lentivirus expressing shRNA for Sema4D (Sema4D shRNA, second lane). MCF-12A cells,
which express very little endogenous Sema4D, were induced to overexpress it through lenti-
viral-mediated transfer of the wild-type construct (Fig 4B, top right panel). We have previously
shown that Sema4D is secreted or shed into the media in cancer cells expressing it through the
action of a protease [15]. To confirm this in our breast cancer lines, we analyzed conditioned
media by silver stain of an SDS-PAGE gel. We observe sSema4D in media conditioned by con-
trol MDA-MB-231 cells and MCF-12A overexpressing Sema4D, but not in MDA-MB-231
with silenced Sema4D or control infected MCF-12A (Fig 4B, bottom panel). We then grew
MC3T3, controls or cells where Plexin-B1 was silenced with shRNA, in media conditioned by
these populations of MDA-MB-231 and MCF-12A cells, with or without the anti-Sema4D
blocking antibody. MDA-MB-231 media suppresses MC3T3-mediated mineralization, unless
Sema4D is silenced in these cells, anti-Sema4D antibody is present, or Plexin-B1 is silenced in
MC3T3 and they can no longer respond to this protein (Fig 4C, left panels). Conversely, media
conditioned by MCF-12A had no effect on mineralization unless these cells were over-express-
ing Sema4D, in which case there was inhibition unless Plexin-B1 was silenced in the osteoblasts
or blocking antibody was present (Fig 4C, right panels). These results are quantified in the bar
graphs in Fig 4D.
It has been shown that osteoblasts from Plexin-B1−/−mice exhibit less GTP-bound, active
RhoA than controls [6]. Our group and others have also shown that ligation of Plexin-B1 by
Sema4D activates RhoA to initiate signaling [3,34]. To investigate mechanism and to deter-
mine the effects of breast cancer-derived Sema4D on production of IL-8 by osteoblasts, we
grew HOB in media conditioned by control MDA-MB-231 or cells with silenced Sema4D, with
and without the Clostridium botulinum toxin C3, which inhibits activation of Rho signaling
pathways, and examined IL-8 production by ELISA. Significant IL-8 production was detected
from cells growing in media conditioned by MDA-MB-231, which was lost where Sema4D was
silenced or Plexin-B1 signaling inhibited in HOB by C3 (Fig 4E). Taken together, these results
suggest that Sema4D from breast cancers can inhibit mineralization by osteoblasts and induce
their production of the osteoclast stimulating factor IL-8 in a RhoA-dependent manner.
Sema4D production by breast cancers promotes lytic skeletal
metastasis
To determine in vivo biological significance of Sema4D expression in breast cancer as it relates
to skeletal metastasis, we injected MDA-MB-231 cells stably expressing luciferase, controls and
those with silenced Sema4D, into the left ventricle of immunosuppressed (nude) mice, which
avoids passage through the lung, and tracked the development of skeletal lesions through bio-
luminescence imaging. Skeletal metastasis concentrated in areas of high bone turnover such as
around the teeth and in the long bones, as previously reported [21]. We detected fewer and
slower growing lesions from cells where Sema4D had been silenced, as shown by photon emis-
sion in Fig 5A. Radiographs also demonstrated less extensive lesions by MDA-MB-231 cells
with silenced Sema4D compared to controls (Fig 5B). These results were confirmed when aver-
aging total photon emissions of all luciferase-expressing lesions, which demonstrated a greater
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Fig 4. Sema4D produced by breast cancer cells inhibits mineralization and promotes RhoA-mediated
production of IL-8 by osteoblasts. A. Breast cancer cell line MDA-MB-231 expresses high levels of
Sema4D in an immunoblot compared to the non-tumorigenic line MCF-12 and T47D, which rarely
metastasize to bone (top panel). GAPDHwas used as the loading control (lower panel).B.MDA-MB-231
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tumor burden in controls compared to MDA-MB-231 with silenced Sema4D (Fig 5C). Mice
injected with tumor cell lines that failed to express Sema4D also exhibited an improved long
term survival compared to controls over the course of the experiment (Fig 5D).
We then examined skeletal metastases by immunohistochemistry and bone histomorpho-
metric analysis for tumor size and the presence of osteoclasts and osteoblasts. Control
MDA-MB-231 generated larger metastatic lesions (Fig 6A, H&E stain, upper left panel) compared
to those expressing Sema4D shRNA (upper right; BM: bone marrow; T: tumor). Sema4D silenc-
ing was confirmed by immunohistochemistry (Fig 6A,middle panels). Immunohistochemistry
for TRAP demonstrated a greater number of osteoclasts in control lesions (Fig 6A, bottom left
panel, arrows) compared to those with silenced Sema4D (bottom right). Using morphometric
analysis of femoral lesions [35], we confirmed that control tumors were larger (Fig 6B), while
tumors made up of cells with silenced Sema4D exhibited greater preservation of bone volume
(Fig 6C). The number of osteoclasts was also greater, on average, in metastases from control
MDA-MB-231 cells (Fig 6D), while the number of osteoblasts was decreased (Fig 6E). Taken
together, these results demonstrate that Sema4D production by tumors results in an increased
number of osteoclasts, a reduction in osteoblasts, and subsequently larger skeletal lesions.
Sema4D from breast cancer alters serum concentration of markers of
bone homeostasis
To determine the effects of tumor Sema4D on bone physiology we tested the serum from
experimental animals by ELISA for markers of bone homeostasis and turnover. Both RANKL
(Fig 7A) and OPG (Fig 7B) were reduced in animals carrying tumors comprised of control
MDA-MB-231, compared to tumors made up of cells with silenced Sema4D. Interestingly,
there was no statistically significant difference between these two populations in the ratio of
RANKL to OPG (Fig 7C), probably related to the fact that they are both products of osteoblasts
and the relative levels between the two different populations might not change. This result also
suggests that RANKL and OPG are not playing a significant role in the metastatic bone resorp-
tion measured in our system. Production of mouse LIX/CXCL5 was higher in controls produc-
ing Sema4D (Fig 7D). Like IL-8, this factor has been associated with bone resorption in mice
[36]. The osteoblast marker osteocalcin was inhibited in controls (Fig 7E), consistent with the
role of Sema4D in osteoblast suppression.
cells infected with lentivirus coding for a scrambled shRNA (C) express Sema4D in whole cell lysates, levels
of which are greatly reduced in cells infected with lentivirus expressing Sema4D shRNA (top left panel). MCF-
12A cells, which express very little endogenous Sema4D (C), are induced to overexpress it through lentiviral-
mediated transfer of the wild-type construct (Sema4D, top right panel). GAPDHwas used as a loading control
(middle panel). sSema4D is present in media conditioned by control MDA-MB-231 cells and MCF-12A
overexpressing Sema4D, but not in MDA-MB-231 with silenced Sema4D or control MCF-12A infected with a
lentivirus containing an empty vector (bottom panel).C.MC3T3-mediated matrix deposition and
mineralization, shown by Alizarin Red stain, is inhibited by media conditioned by control MDA-MB-231 (C,
first column, left panels), but not in those where Sema4D is silenced by shRNA (Sema4D shRNA, second
column, left). When Plexin-B1 is silenced in MC3T3 (PB1 shRNA, second row), or anti-Sema4D blocking
antibody is administered (bottom row), mineralization is restored. Media conditioned by control MCF-12A had
no effect on mineralization (C, first column, right panels) unless these cells were over-expressing Sema4D, in
which case there was inhibition (Sema4D, second column, right). Mineralization was restored when Plexin-
B1 was silenced in osteoblasts (PB1 shRNA, second row) or blocking antibody was present (bottom row).
Isotype matched IgG was used as a control for both experimental groups.D.Quantification of results by
absorbance at 405 nm (Y-axis) of the results shown in (B) from three independent experiments. MDA-MB-
231 cells, left bar graph; MCF-12A, right. E. Incubation of the human osteoblast line HOB with media
conditioned by MDA-MB-231 induces production of IL-8 (concentration in ng/ml, Y-axis), unless Sema4D is
silenced in MDA-MB-231 by shRNA or Plexin-B1 signaling to RhoA is inhibited by addition of theClostridium
botulinum toxin C3 (*, p 0.05; **, p 0.01).
doi:10.1371/journal.pone.0150151.g004
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Discussion
In recent years, new discoveries have expanded the role of plexins and semaphorins beyond
that of nerve guidance and fasciculation and into the realm of bone metabolism. For example,
Fig 5. Xenografts with silenced Sema4D exhibit fewer and smaller lesions and longer survival
compared to controls in a mousemodel of skeletal metastasis. A.MDA-MB-231 expressing luciferase,
controls (C) and with silenced Sema4D (Sema4D shRNA), were introduced into the systemic circulation of
immunocompromised mice and developing lesions tracked by BLI. Representative lesions developing after 7
days (top row) and 34 days (bottom row) are shown. Luminescence, related to the number of collected
photons, is shown on the right. B. Radiographs of representative lesions are shown.C.Mice grafted with
MDA-MB-231 with silenced Sema4D exhibited fewer lesions (tumor burden, 106 photons/sec, Y-axis)
compared to controls (**, p 0.01). D. Kaplan–Meier curve reveals that mice grafted with MDA-MB-231 with
silenced Sema4D exhibited longer survival compared to controls.
doi:10.1371/journal.pone.0150151.g005
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Fig 6. Sema4D promotes larger metastatic lesions, with fewer osteoblasts andmore osteoclasts. A.
Hematoxylin and eosin (H&E) stained sections of control (C) tumors or those with silenced Sema4D
(Sema4D shRNA) metastatic to the femur (top row; T, tumor; BM, bone marrow; original magnification 10x).
Control tumors on average were larger than those from cells where Sema4D was silenced. Sema4D
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Plexin-A1, which binds to class 3 semaphorins, has been implicated in control of bone density
[37]. Indeed, it is now known that Semaphorin 3B promotes osteoclastogenesis and osteopenia
in a mouse model [38] and that Semaphorin 3A exerts an osteoprotective effect by suppressing
bone resorption and increasing bone formation [39]. The class 3 semaphorins have not been
conclusively linked to regulation of skeletal metastasis in malignancy, but they are known to
have inhibitory effects on breast cancer progression through their anti-angiogenic effects,
which is lost in a subset of triple negative breast cancers (TNBC) and therefore might represent
a potential target for therapy [40].
silencing was confirmed by immunohistochemistry in tumor tissues (second row; original magnification 40x).
Osteoclasts attached to bone in the tumor microenvironment were identified by TRAP immunohistochemistry
(TRAP, bottom row, positive cells indicated by arrows; original magnification 40x).B. Histomorphometric
analysis for total tumor area in formalin fixed paraffin embedded specimens confirmed that control tumors
were larger (tumor area in mm2, Y-axis).C. Tumors made up of cells with silenced Sema4D exhibited greater
preservation of bone volume (bone volume expressed as a percentage of total tissue volume, Y-axis). D. The
number of osteoclasts present in lesional bone, as determined by TRAP positivity, was greater in control
tumors (number of osteoclasts per mm2 of bone surface, Y-axis). (E) The number of osteoblasts in lesional
bone was higher in tumors where Sema4D was silenced (number of osteoblasts per mm2 of bone surface, Y-
axis; *, p 0.05).
doi:10.1371/journal.pone.0150151.g006
Fig 7. Silencing Sema4D in breast cancer changes serum levels of mediators of bone remodeling. A.
ELISA performed for RANKL, an osteoblast-derived pro-osteoclastogenic factor, revealed higher levels in
mice bearing tumors fromMDA-MB-231 where Sema4D was silenced, suggestive of enhanced osteoblast
activity, when compared to controls (RANKL levels in pg/ml, Y-axis).B.OPG levels are also higher in mice
with tumors with silenced Sema4D (pg/ml, Y-axis).C. The ratio of the antagonists RANKL/OPG is not
significantly different between the two populations, indicating the importance of other factors in the bone
resorption observed in our model. D. In support of in vitro findings, mice bearing control tumors expressing
Sema4D demonstrated significantly higher levels of serum LIX/CXCL5 (pg/ml, Y-axis). E. As expected,
osteocalcin, a marker of osteoblast activity, is higher in the serum of Sema4D shRNA populations compared
to controls (ng/ml, Y-axis; *, p 0.05; n.s., not significant).
doi:10.1371/journal.pone.0150151.g007
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In normal bone maintenance, osteoblast differentiation needs to be suppressed until bone
resorption is completed. This occurs in many ways, but Negishi-Koga, et al. demonstrated that
osteoclasts suppress bone formation by producing Sema4D, which acts through its receptor
Plexin-B1 on osteoblasts to activate the Sema4D–Plexin-B1–RhoA pathway [6]. It is believed
that this suppresses osteoblast differentiation by attenuating IGF-I signaling [41] while simul-
taneously limiting the ability of cells to signal through integrins and adhere, spread, and
migrate, functions essential for proper maintenance of bone [42]. One obvious consequence of
this discovery is the value of Sema4D inhibition in the arrest of osteopenia. Sema4D-/- mice
demonstrate a mild osteosclerotic phenotype, identical to Plexin-B1−/−mice and mice express-
ing dominant-negative RhoA, so this signaling pathway could have therapeutic implications in
diseases such as osteoporosis. As cancer researchers, we immediately recognized another impli-
cation of these findings for skeletal metastasis. Some malignancies exhibit tropism for bone,
and even in early stages form lesions which are osteolytic in nature. Stimulation of osteoclasts
or direct resorption of bone by cancer cells would seem to be the obvious mechanism for bone
lysis, but inhibition of osteoblasts, along with their negative feedback on osteoclasts, would also
offer a distinct advantage in establishing a lytic bone lesion.
We have previously shown that many cancers, particularly those of epithelial origin, overex-
press Sema4D [7] and therefore wanted to examine the biological significance in bone metasta-
sis. We chose to examine breast cancer, as many are known to exhibit lytic skeletal lesions, but
multiple myeloma and some prostate cancers also follow a similar progression of disease. Here
we confirm that Sema4D inhibits osteoblast differentiation and ability to form a mineralized
matrix in vitro in a Plexin-B1-dependent manner. We have shown that much of Plexin-B1 sig-
naling, including migration of endothelial cells and activation of AKT and ERK, are mediated
by the small GTPase RhoA [43]. Upon further investigation, we observed that IL-8 production
by osteoblasts was dependent upon Plexin-B1 signaling to RhoA, resulting in indirect activa-
tion of osteoclasts. While RhoA signals through the cytoskeleton to influence cell migration,
adhesion, and stress fiber formation, it also regulates gene expression, which could be the
mechanism of IL-8 activation. However, the exact pathways engaged by RhoA and the down-
stream effectors necessary for IL-8 production by osteoblasts remain to be elucidated.
We observed that silencing of Sema4D expression in breast cancer cells through shRNA
resulted in smaller and fewer skeletal metastases over time and greater life expectancy in a
mouse model compared to controls. It should be noted, however, that despite differences in
mineralization between these two populations, including a reduction in osteoblasts and
enhanced osteoclastogenesis in metastatic lesions where cells were expressing Sema4D, we can-
not rule out effects of Sema4D as a generalized factor influencing tumor aggressiveness. Indeed,
overexpression of Sema4D (along with Plexin-B1) is correlated with histological tumor type,
TNM stage, and metastasis in prostate and colon cancers [44,45] and a worse prognosis in
both soft tissue sarcomas [46] and osteosarcoma [47]. Our group and others have shown that
Sema4D promotes angiogenesis [3,4], so restriction of blood vessel growth into the metastatic
lesions also is one possible contributor to the observed reduction in growth. We did not specifi-
cally measure breast cancer cell proliferation, invasion or vascularity in our experiments in an
attempt to avoid duplication of already published reports, but Sema4D (or loss thereof) could
certainly influence progression of metastatic lesions through these mechanisms. Nevertheless,
our findings could have implications in therapy for TNBC, which lack dependence upon estrogen
receptor, progesterone receptor and HER2 signaling and are therefore difficult to treat. Sema4D
has been shown to activate Erb-B2/ HER2 (through Plexin-B1) to promote breast cancer metas-
tasis [48], and although TNBC would probably fail to respond similarly, it's blockade would be
worth investigating in these malignancies as a supplemental treatment along with more conven-
tional approaches, if not to block cancer growth then to inhibit skeletal metastasis.
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We propose a model of lytic skeletal metastasis where breast cancer cells newly colonizing a
site in bone produce Sema4D which inhibits osteoblasts and causes them to produce IL-8, pro-
moting osteoclast function. We do not postulate a role for Sema4D/Plexin-B1 signaling in the
ability of certain tumor cell types to home to bone, but once at the site the end result of such alter-
ation in osteoblast-osteoclast communication would be a more favorable microenvironment in
which to establish a metastatic niche. The BLI results and histomorphometric analysis tend to
support this model, as they describe a profile of decreased osteoblast function, enhanced osteo-
clast activity and larger, more numerous lesions when Sema4D is expressed in tumor cells. The
serum ELISAs also lend support to our model. RANKL and OPG, antagonists in the regulation
of osteoclast activity and bone resorption and mainly products of osteoblasts, are both lower in
the serum of mice bearing tumors comprised of control cells still capable of producing Sema4D.
However, the ratio of RANKL to OPG would be expected to be different between the two popula-
tions if these factors were playing a major role in tumor-induced bone resorption. We failed to
observe this, suggesting instead that other factors are more important. We believe that not only is
Sema4D significant in this process through its ability to directly inhibit osteoblasts but that its
induction of LIX/CXCL5, which was higher in the serum of mice with control tumors, offers fur-
ther stimulation of bone resorption through support of osteoclastogenesis. LIX/CXCL5 previ-
ously has been implicated in bone resorption in a mouse model of periodontal disease [36].
Sema4D in these metastatic lesions could come from different sources. For example,
Sema4D is produced by osteoclasts, and we have demonstrated its expression in primary breast
cancers in a tumor tissue array [7], but lymphocytes present in the metastatic microenviron-
ment would produce Sema4D as well. To determine the importance of cancer cell Sema4D on
bone metastasis, we eventually would like to investigate its expression in biopsies of primary
human breast cancers and tumors metastatic to bone to see if there is any correlation with
establishment of lytic skeletal metastases, as there seems to be for the cell lines we studied in
vivo. The same difficulties would apply to IL-8 with regards to its origins but also its mecha-
nism of production, particularly the link between IL-8 and NF-κB activation by osteoblast
Plexin-B1. Such an analysis would require genetic targeting of osteoblasts in mice order to
abrogate responses to Sema4D or the ability to generate LIX/CXCL5. Unfortunately, although
mice are available that express tamoxifen responsive Cre in osteoblasts (and odontoblasts),
there do not exist mice with floxed LIX/CXCL5. Finally, IL-8 likely is not the only factor pro-
duced by osteoblasts upon exposure to Sema4D that may enhance the establishment of skeletal
metastases, as Sema4D is known to induce other cytokines [49]. This could be investigated by
an HOB cytokine array for production of other proteins that influence osteoblast and osteoclast
functioning, such as TGFβ, BMP2, and RUNX2, a key regulator of bone differentiation that has
also plays a role in cell cycle regulation and tumorigenesis.
Like many malignancies, the molecular pathogenesis of breast cancer is complex, and the
standard of care is administration of radio- and/or chemotherapy to induce death in the rapidly
growing cancer cells. An advantage of studying ways to suppress metastasis instead of attempt-
ing to kill cancer cells is that the aggressive treatments necessitated by advanced disease can fail
due to patient intolerance and the generation of resistant cancer cell clones arising from geneti-
cally labile progenitors under the selective pressures of cytotoxicity. Though treatable in its
early stages, breast cancers eventually acquire the ability to proliferate inappropriately, avoid
natural defenses, and resist therapy, suggesting the urgent need for innovative targets and strat-
egies that suppress growth and invasion via an outcome other than cell killing. While the sema-
phorins and the plexins are crucial for cell adhesion, migration, invasion and metastasis, they
have never been shown to be oncogenic or required for cell survival. Therefore, approaches
directed against these proteins would not demonstrate toxicity to tumor cells, a feature that
would represent an enormous advance in the field.
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In bone homing malignancies, bisphosphonates are used to suppress skeletal metastases and
the resulting complications of bone pain, pathologic fractures, hypercalcemia and other skele-
tal-related events, but this form of treatment inhibits osteoclasts and arrests bone remodeling,
leading to “frozen bone” skeletal fragility and bisphosphonate-induced osteonecrosis of the
jaw. Further benefits of our studies are that targeting Sema4D for inhibition would be a viable
alternative to bisphosphonates, since it would not inhibit osteoclasts nor restrict skeletal
remodeling and therefore could elicit an improved therapeutic result without the debilitating
side effects of jaw osteonecrosis. Toxicity towards normal tissues would also not be an issue, as
research into B-family plexins suggests that while important in normal development and
malignancy, they are redundant for homeostasis of mature tissues [50].
Conclusions
The findings presented here demonstrate that Sema4D enhances skeletal metastasis and could
represent a new therapeutic target in the suppression of skeletal metastases for a subset of bone
homing malignancies such as breast cancer.
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